Carnosine And Anti-Ageing
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
Most of us reach for calcium when we think about bone health. Maybe vitamin D if we’re keeping up with the headlines. But what if the nutrient your bones actually need most is one you’ve barely heard of — and one that’s almost entirely absent from the modern Western diet? Vitamin K2 has been sitting quietly in the research literature for decades, doing something genuinely fascinating: directing calcium to go *into* your bones rather than into your arteries. The Vitacuity database returned 15 papers on this topic, and what they show is a story worth telling carefully — because this isn’t a miracle cure, but it might be one of the most overlooked pieces of the bone health puzzle.
To understand why K2 matters, you first need to know about a protein called osteocalcin. Think of osteocalcin as a kind of biological glue that helps bind calcium into your bone matrix — the scaffolding that gives bone its density and strength. But here’s the catch: osteocalcin only works properly once it’s been “activated,” and it can only be activated by vitamin K [3].
Without enough K2, osteocalcin circulates in an inactive, undercarboxylated form (you’ll see it called ucOC in research). It can’t do its job. Calcium, instead of being incorporated into bone, ends up floating around — and potentially depositing in places you really don’t want it, like your arterial walls [9].
This is why K2 is often described as the body’s traffic director for calcium. It activates two critical proteins: osteocalcin (which pulls calcium into bone) and matrix GLA protein (MGP) (which prevents calcium from depositing in soft tissues and blood vessels) [9]. The two work together, and getting enough K2 keeps both systems running as they should.
The main form you’ll see in supplements is menaquinone-7 (MK-7) — the long-chain form of K2 that stays active in the body far longer than other forms and is considered the most effective at improving these biological markers [2].
Evidence grade: Promising — double-blind RCT, but a single trial
One of the most cited studies in this area is a three-year, double-blind randomised controlled trial published in 2013 [2]. Researchers gave postmenopausal women a low dose of MK-7 — just 180 micrograms per day — and tracked what happened to their bones over three years.
The results were meaningful. MK-7 supplementation significantly decreased the age-related decline in bone mineral density and bone strength compared to placebo. Crucially, the researchers also saw improvements in measures of bone strength at the femoral neck (the part of the hip most prone to fracture) — an area where fractures can be life-changing for older women [2].
This matters because it suggests K2 isn’t just nudging a biomarker — it may be producing real, structural changes in bone. Three years is also a decent study duration for bone research, which adds some weight to these findings. That said, this is a single trial, and we need to be honest that one well-designed RCT, however good, isn’t the same as a settled body of evidence.
Evidence grade: Promising — human trial data, but moderate sample sizes
A 2007 study looked specifically at whether high vitamin K2 intake could improve not just bone mineral density (BMD) — the standard measure — but bone geometry and structural strength indices at the hip [6].
The results were interesting and somewhat nuanced. K2 supplementation improved bone mineral content and femoral neck width — markers of bone geometry and structural resilience — but did *not* significantly improve the standard DXA-BMD score [6]. This is an important distinction. Standard DXA scans measure bone density but don’t fully capture the quality of a bone’s architecture. The finding suggests K2 may be working on bone *structure* in ways that conventional density measurements underestimate [6].
A 2016 study extended this picture further, looking at trabecular bone microarchitecture — essentially the internal 3D scaffolding of bone — using high-resolution imaging at the tibia [10]. This study found that MK-7 helped prevent age-related deterioration of this internal bone architecture in postmenopausal women, a finding that goes beyond what a simple density scan would show [10].
Evidence grade: Promising — multiple human trials, consistent direction, but methodological variation
Several studies suggest that vitamin K2 and vitamin D3 work synergistically on bone health — and this is a recurring theme across the literature [3][5][13].
A 2002 randomised controlled trial involving 172 postmenopausal women with osteopenia or osteoporosis compared four approaches over 24 months: vitamin K2 alone, vitamin D3 alone, the two combined, and a control group [13]. The findings were striking:
– Combined K2 + D3 therapy: bone mineral density increased by +4.92% over 24 months – Vitamin K2 alone: bone mineral density increased by just +0.135% – The combination outperformed either nutrient on its own [13]
The researchers also measured coagulation function — a safety concern sometimes raised about K2 — and found that while coagulation activity did increase, it stayed firmly within normal physiological range throughout the trial [13].
This synergy makes biological sense: vitamin D helps the body absorb calcium and promotes the *production* of osteocalcin, while vitamin K2 then *activates* that osteocalcin to do its job. They’re working on different steps of the same process [3].
Evidence grade: Promising — some human trial data, but methodological limitations acknowledged
The ultimate test of any bone health intervention isn’t bone density numbers — it’s whether it actually prevents fractures. The evidence here is encouraging but needs honest qualification.
A two-year randomised open trial involving 167 osteoporotic patients found that K2 treatment had a meaningful impact on vertebral fracture rates [11]:
– Control group fracture rate: 0.212 events per year – K2 treatment group fracture rate: 0.098 events per year (p = 0.0186)
That’s roughly a halving of fracture incidence over the trial period [11]. The same study found that the K2-treated group maintained their lumbar bone mineral density over two years, while the control group saw a -3% decline [11].
A 2001 review of the human intervention literature at that time concluded that vitamin K — and particularly K2 — had demonstrated the ability to both increase bone mineral density in osteoporotic patients and reduce fracture rates across multiple studies [3]. However, the same review acknowledged that many of these studies used high doses of K2, which was a legitimate criticism of the evidence base at the time.
A 2013 review struck a more cautious note, concluding that while supplementation with K1 and K2 *may* reduce fracture risk, the trials examining fractures as an outcome have methodological limitations — and that larger, better-designed trials are still needed [15].
Evidence grade: Promising — double-blind RCT dose-finding data
One of the most practically useful studies in this area is a 2015 double-blind RCT that set out to find the effective *minimum* daily dose of MK-7 for improving osteocalcin activation [12].
Study 1 tested 60 postmenopausal women across four dose groups (0, 50, 100, and 200 micrograms of MK-7 daily) for four weeks. The carboxylated-to-undercarboxylated osteocalcin ratio — the key biomarker of K2’s action in bone — improved significantly in the 100mcg and 200mcg groups, but not in the 50mcg group [12].
Study 2 confirmed this with a 12-week trial in 120 subjects aged 20-69 (both men and women), finding that 100mcg daily of MK-7 significantly improved the osteocalcin activation ratio compared to placebo [12].
The practical takeaway: 100 micrograms of MK-7 per day appears to be the effective threshold for improving the biological markers associated with bone health. This is also the dose used in most of the positive RCTs reviewed here.
Evidence grade: Promising — human and mechanistic data
One of the more intriguing aspects of K2 research is what it suggests about the wider calcium management problem. A 2015 paper noted a concerning pattern: while supplemental calcium promotes bone mineral density, elevated calcium supplementation has been associated with increased risk of cardiovascular events — specifically, accelerated calcium deposits in arterial walls [9].
This is where K2’s role as a calcium traffic director becomes particularly relevant. By activating matrix GLA protein (MGP), K2 actively *inhibits* arterial calcification and arterial stiffening [9]. In populations with adequate K2 intake, the risk of vascular calcium deposition appears lower. The paper concluded that for anyone taking calcium supplements, adequate K2 intake may be especially important — ensuring calcium ends up in bones rather than arteries [9].
To be clear: this is mechanistic and observational evidence, not a proved causal chain from supplementation to cardiovascular outcomes. But it adds biological plausibility to why K2 matters beyond just bone density scores.
Let’s be honest about the gaps, because they matter.
The fracture evidence has real limitations. The 2013 systematic review [15] put it plainly: randomised controlled trials of K2 supplementation in *white* populations did not consistently increase bone mineral density at major skeletal sites. Much of the strongest fracture and BMD data comes from Japanese populations [11][13], where K2 (particularly as MK-4, a shorter-chain form) has been used medically for decades at very high pharmacological doses — far higher than typical supplement doses in the West. Whether these results translate directly to Western populations taking standard supplement doses is a legitimate open question.
High doses vs. low doses remain a tension in the literature. Some of the most impressive fracture and BMD data comes from studies using very high pharmacological doses of K2 [3][4][11]. The more recent low-dose MK-7 trials (100-180mcg) show promising effects on biomarkers and some bone density measures, but the fracture outcome data at low doses is thinner.
K1 vs. K2 is still being resolved. The 2013 review notes that K1 at lower doses may also benefit bone health, particularly when combined with vitamin D [3][15]. The relative contributions of different forms of vitamin K remain an active area of research.
Who responds may vary. One trial found that patients with an ApoE4 genetic variant showed less BMD response to K2 treatment [11] — a reminder that individual genetic variation may influence how well this intervention works for any given person.
Long-term safety at supplemental doses is understudied. The available evidence suggests K2 is very well tolerated, and the 2002 RCT found no adverse effects on coagulation even after two years of supplementation [13]. However, K2 can interact with anticoagulant medications like warfarin. This is a real clinical consideration for anyone on blood-thinning medication.
The 2013 review [15] concluded that there is currently “not enough evidence to recommend the routine use of vitamin K supplements for the prevention of osteoporosis and fractures in postmenopausal women” — and we think that’s a fair reflection of where the formal evidence stands. But as you’ll see below, that doesn’t mean the picture is simple.
Here’s how a sensible, informed person should think about this.
The evidence for K2 is genuinely promising but not yet definitive. The biomarker evidence — that K2 activates osteocalcin, reduces undercarboxylated osteocalcin, and improves the biological machinery of bone mineralisation — is strong and consistent [2][3][12]. The structural bone evidence (geometry, microarchitecture) is encouraging [6][10]. The fracture data is suggestive but methodologically imperfect [11][15]. The combination with vitamin D3 appears to be more effective than either alone [13].
What should you actually do?
If you’re over 40, particularly if you’re a postmenopausal woman, and you’re thinking about bone health, K2 deserves a place in your thinking alongside calcium and vitamin D. The effective dose from the best-designed trials appears to be 100-180mcg of MK-7 daily [2][12]. K2 is fat-soluble, but unlike vitamin A, it has a very low toxicity profile at these supplement doses — the evidence does not flag safety concerns at normal supplemental amounts [4].
The practical logic is compelling: K2 is nearly absent from processed and junk food and is low even in many healthy Western diets [9]. The biological case for why deficiency matters is well-established. The supplement cost is low. The safety profile at normal doses is good. The upside — potentially better bone structure, reduced fracture risk, and a more sensible calcium distribution in the body — is genuinely meaningful.
If you’re already taking vitamin D3 (and if you’re in the UK, you almost certainly should be), taking MK-7 alongside it is the smarter approach. That combination appears to be where the best bone health signal sits [3][5][13].
One important exception: if you are taking warfarin or any anticoagulant medication, talk to your GP before adding K2. K2 affects the clotting system and can interact with these drugs. This is a real contraindication, not a generic disclaimer.
For everyone else? The risk of K2 deficiency is real. The supplement is safe and cheap. The evidence points in a clear direction, even if it isn’t yet watertight. A sensible, informed person would supplement.
[1] Vitamin K linked to bone strength. (2007). *Journal not specified in source data.*
[2] Knapen MHJ et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. (2013). *Journal not specified in source data.*
[3] Vermeer C et al. Vitamin K and bone health. (2001). *Nutrition.* DOI: 10.1016/s0899-9007(01)00709-2
[4] Hamidi MS et al. Vitamin K2: a novel therapy for osteoporosis. (2010). *Journal not specified in source data.*
[5] Effect of combined administration of vitamin D3 and vitamin K2. (2004). *Journal not specified in source data.*
[6] Braam LA et al. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. (2007). *Journal not specified in source data.*
[7] What Is Vitamin K2 and Does It Have an Impact on Bone Health? (2016). *Journal not specified in source data.*
[8] Vitamin K2 treatment for osteoporosis: what is the evidence today? (2007). *Journal not specified in source data.*
[9] Maresz K. Proper Calcium Use: Vitamin K2 as a Promoter of Bone and Cardiovascular Health. (2015). *Journal not specified in source data.*
[10] Knapen MHJ et al. Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women. (2016). *Journal not specified in source data.*
[11] Vitamin K2. (1998). *Journal not specified in source data.*
[12] Tsugawa N et al. Low-Dose Daily Intake of Vitamin K2 (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trial. (2015). *Journal not specified in source data.*
[13] Ushiroyama T et al. Effect of continuous combined therapy with vitamin K2 and vitamin D3 on bone mineral density and coagulofibrinolysis function in postmenopausal women. (2002). *Maturitas.* DOI: 10.1016/s0378-5122(01)00275-4
[14] Role of vitamin K. (2020). *Gynecological Endocrinology.* DOI: 10.1080/09513590.2019.1689554
[15] Weber P et al. Vitamin K and bone health. (2013). *Journal not specified in source data.*
Quick Read Carnosine is a small molecule your muscles naturally produce that declines with age. Research suggests it fights three
Quick Read CoQ10 is a molecule found in your cells’ power stations (mitochondria) that helps convert food into energy your
